Similar articles

• [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].

  Selbmann HK. Selbmann HK. MMW Fortschr Med. 2009 Aug 20;151(34-35):6. MMW Fortschr Med. 2009. PMID: 19771776 German. No abstract available.
• [Physician and pharmaceutical industry. II. Postmarketing surveillance].

  Offerhaus L. Offerhaus L. Ned Tijdschr Geneeskd. 1992 Jan 4;136(1):36-41. Ned Tijdschr Geneeskd. 1992. PMID: 1728761 Dutch. No abstract available.
• [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].

  Gleiter CH, Bieck PR. Gleiter CH, et al. Fortschr Med. 1991 Jul 20;109(21):429-31. Fortschr Med. 1991. PMID: 1916572 German. No abstract available.
• Monitoring adverse drug reactions in the postmarketing phase.

  Hoigné R, Hottinger S. Hoigné R, et al. Pharm Acta Helv. 1988;63(1):2-12. Pharm Acta Helv. 1988. PMID: 3283774 Review. No abstract available.
• Use of an algorithm to evaluate published reports of adverse drug reactions.

  Case B, Oszko MA. Case B, et al. Am J Hosp Pharm. 1991 Jan;48(1):121-2. Am J Hosp Pharm. 1991. PMID: 2000870 Review. No abstract available.